כנסי האגודה

ב- 14-15 באפריל התקיים הכנס השנתי ה-44 של האגודה האנדוקרינית עם תוכנית מדעית ונוכחות מרשימה של משתתפים. בכנס היו הרצאות מליאה של Clifford Rosen על הקשר בין רקמת שומן לאוסטאופורוזיס, Silvia Montecone על גנטיקה של Primary Aldosteronism והרצאה מרגשת של Erol Cerasi נשיא האגודה לשעבר. בכנס הוצגו קרוב ל 100 עבודות וכמחצית מהן כפוסטר.

השנה ועד האגודה העניק אות חבר כבוד (Honorary Membership) לחברים הבאים: פרופ’ ארול צרסי, פרופ’ אלכס צפרירי, פרופ’ ברונו לוננפלד וד"ר אליצור חזני.
ועד האגודה רוצה להודות לפרופ’ יוסי אורלי על השקעתו בעבודה מוצלחת כיו”ר הכנס.
תוכנית הכנס ומבחר הרצאות מצולמות מתועדות באתר.

פרסים ומלגות מחקר 2015 של האגודה

בכנס השנתי חולקו פרסים ומלגות מחקר. זוכת פרס לינדנר היא ד"ר איילת ארז. זוכת פרס חוברס היאד"ר יעל לוי שגרה. העבודה הקלינית המצטיינת – פרופ’ ירדנה טננבאום-רקובר. עבודת בייסיק מצטיינת – יעל קופרמן. פוסטרים מצטיינים – עדי וינברג, מאיר פרנקל, מיטל ג’רפי- כהן. מענקי מחקר בסכום 30,000 מקרן האגודה חולקו לשלושה חוקרים: ארן גרשון, אוריאן שליט ודנה הודרלנד.
ועד האגודה מברך את כל הזוכים.

מלגות השתתפות לכנסים בינלאומיים לחוקרים צעירים

ברצוננו להזכיר את המועדים להגשת בקשה למלגות לחוקר צעיר המציג עבודת מחקר בכנס בינלאומי.
מועד ראשון: 31 במאי, מועד שני: 30 בנובמבר בכל שנה. קריטריונים למועמדות בלינק הבא

יום עיון על טיפול בסרטן תירואיד

ב 29 באפריל התקיים כנס ארצי על סרטן התירואיד בבית חולים רמב"ם, בשיתוף פעולה של אא"ג,
אנדוקרינולוגיה, אונקולוגיה ורפואה גרעינית. בכנס נוכחו כ-300 משתתפים. הכנס שם דגש על controversies בטיפול בספקטרום שבין היקף הניתוח ראשוני עד לטיפולים ביולוגים במחלה מתקדמת. פרופ’ Mike Tuttle מניו יורק ופרופ’ Ezra Cohen מסן דיאגו שיתפו אותנו בניסיון שלהם בתחום Redifferentiation therapy והשימוש ב TKI’s בחולים עמידים ליוד. ברכות לד"ר שגית סולוטוב מהמכון האנדוקריני ופרופ’ גיל זיו מנהל אא"ג, שניהם מבית חולים רמב"ם, על הארגון המוצלח.

רשימת מפגשים וכנסים קרובים

• ב 06/05/15 – European Congress on Obesity (Prague)
• ב 13/05/15 – 24th Meeting of the AACE (Nashville)
• ב 14/05/15 – The Adrenal Symposium (מרכז רפואי בני ציון חיפה)
• ב 16/05/15 – European Congress of Endocrinology (Dublin)
• ב 05/06/15 – 75th American Diabetes Association annual meeting (Boston)
• ב 17/06/15 – UPCP 2015 (תל אביב)
• ב 09/07/15 – מפגש Israel Group for Neuroendocrine Tumors (רמת-גן)
• ב 09/09/15 – European Society for Paediatric Endocrinology (Barcelona)
• ב 14/09/15 – 51st Meeting of the EASD (Stockolm)
• ב 07/10/15 – ISPAD annual meeting (Australia)
• ב 09/10/15 – ASBMR annual meeting (Seattle)
• ב 18/10/15 – ATA and International Thyroid Congress (Orlando)
• ב 30/11/15 – World Diabetes Congress (Vancouver)
• ב 01/04/16 – Endocrine Society’s 98th Meeting (Boston)
• ב 30/04/16 –  Pediatric Endocrine Society annual meeting (Maryland)
• ב 25/05/16 –  25th meeting of the AACE (Orlando)
• ב 27/05/16 –  17th European Congress of Endocrinology (Munich)
• ב 01/06/16 –  European Congress on Obesity (Gothenburg)
• ב 31/08/16 –  International Congress of Endocrinology (Beijin)
• ב 10/09/16 –  ESPE annual meeting ׁ(Paris)
• ב 16/09/16 –  ASBMR annual meeting (Atlanta)
• ב 21/09/16 –  ATA annual meeting (Denver)
• ב 06/11/16 –  8th Congress of the GRS and IGF society (תל אביב)

ATA Revised Guidelines for Medullary Thyroid Cancer
להמשך קריאה

AACE Updates Guidelines For Management Of T2D.
New guidelines for T2DM from AACE are know available online
להמשך קריאה

ATA Guidelines For Managing Thyroid Nodules In Children.
ATA released first guidelines managing benign and cancer thyroid nodules in children להמשך קריאה

MicroRNA Gene Expression Classifier For Benign, Malignant Thyroid Nodules.
PDI, a healthcare commercialization company, introduced ThyraMIR, the first microRNA gene expression classifier to tests benign and malignant thyroid nodules. ThyraMIR is used with ThyGenX, a genetic mutation panel from PDI’s parent company Interpace Diagnostics, it has 94% NPV and 74% PPV at a cancer prevalence of 32%
להמשך קריאה

IOM To Change Name To National Academy Of Medicine.
On July 1 the Institute of Medicine (IOM) will be renamed the National Academy of Medicine as part of a broader internal reorganization by the National Academy of Sciences to integrate the research on matters of science, engineering and health. להמשך קריאה

Glyburide For Gestational Diabetes Linked To Higher Risk Outcomes 
Study in JAMA Pediatrics suggests women with gestational diabetes on glyburide had higher relative risk for adverse pregnancy outcomes. The 110,879-woman study revealed that compared with women on insulin, women on glyburide delivered babies with a 41% higher relative risk for being admitted to the NICU, a 63% higher risk for respiratory distress, and a 43% higher risk for large for gestational age.
להמשך קריאה

Israel Device Maker Licenses Artificial Pancreas Technology To Medtronic.
Israel-based DreaMed Diabetes announced a partnership with US-based Medtronic in which it has licensed its artificial pancreas technology, GlucoSitter, to be integrated into Medtronic’s insulin pumps. GlucoSitter is an automated system for regulating glucose levels, and it directs the pump to administer the correct insulin dose to the body.
להמשך קריאה

Weight Loss In Middle Age May Lead To A Loss Of Bone Density In Women.
A study in JCEM suggests weight loss in middle age women may lead to loss BMD.
להמשך קריאה

Brown Adipose Tissue Transplant May Reduce Weight In Leptin-Deficient Mice.
A study in Endocrinology, indicated transplantation of brown adipose tissue from donor animals appeared to reduce weight gain in leptin-deficient Ob/Ob mice, presumably by enhancing the activity of endogenous brown fat.
להמשך קריאה

FDA Analysis Finds Saxagliptin May Be Associated With Increased Death Risk.
Preliminary data reviewed by FDA suggests Onglyza (saxagliptin) could be associated with a higher mortality risk. The analysis raises new concerns over a class of diabetes medications, DPP-4 inhibitors. A post-marketing study of Onglyza, which involved more than 16,000 patients, showed the drug increased hospitalizations for heart failure by 27% and increased all-cause mortality, although the FDA noted deaths in those patients often involved multiple factors, according to briefing documents.
להמשך קריאה

Maternal Diabetes and Autism in Offspring 
In a retrospective longitudinal study including 322,323 singleton children born in 1995-2009 at Kaiser Permanente Southern California (KPSC) hospitals, exposure to maternal GDM diagnosed by 26 weeks’ gestation was associated with risk of Autism (HR 1.21).
להמשך קריאה

MiniMed 530G: An Insulin Pump With Low-Glucose Suspend Automation
The FDA has approved the MiniMed 530G (Medtronic), an insulin pump used in combination with a continuous glucose monitoring sensor (Enlite) that can stop delivery of insulin when interstitial glucose reaches a prespecified low level. It is the only sensor-augmented insulin pump
להמשך קריאה

Oral Insulin on elicits Immune Responses in Children at High Risk for T1DM
A study in JAMA of children at high risk for type 1 diabetes, daily oral administration of 67.5 mg of insulin, compared with placebo, resulted in an immune response without hypoglycemia. These findings support the need for a phase 3 trial to determine whether oral insulin can prevent islet autoimmunity and diabetes in such children
להמשך קריאה

Report Details Efforts To Pressure FDA Into Approving Weight-Loss Drugs.
The Milwaukee Journal Sentinel outlines the money spent, about $60 million, by seven US drug companies – Orexigen, Takeda, Eisai, Arena, Vivus, Novo Nordisk and Shire Pharmaceuticals – who were at the center of efforts to get FDA approve new diet drugs.
להמשך קריאה

Coronary Risk Among People With TSH On Upper End Of Normal.
A study in JAMA Internal Medicine suggests differences in thyroid function within the population reference range didn’t appear associated with coronary risk. Examining data on 55,412 individuals from 14 cohorts with TSH in the upper part of the reference range (0.45 to 4.49 mIU/L) and not pre-existing thyroid or cardiovascular disease, researchers found people with TSH at 3.50 to 4.49 mIU/L had a similar risk of coronary heart disease (HR 0.97) and death from coronary disease (HR 0.94) than those with 0.45 to 1.49 levels.
להמשך קריאה

Novo Nordisk Launches Obesity Treatment In US Market.
Novo Nordisk has launched its obesity treatment, Saxenda (liraglutide injection), in the USA. The official cost of the treatment is $1,068 per month.
להמשך קריאה

Study suggests potential mechanism which may link GLP-1 to pancreatitis.
MedPage reports that a research letter published in the journal Diabetes Care suggests that postprandial increases in lipase and amylase seen with GLP-1 drugs didn’t happen in patients who weren’t on those medications, providing a potential mechanism by which the drugs may be linked to pancreatitis. The 30-patient study revealed that neither of the two enzymes increased after meals in patients with T2DM or healthy controls.
להמשך קריאה

Endocrinologists Among Lowest-Paid US Physicians.
Endocrinologists remain among the lowest-paid physicians in the United States – third from the bottom, ahead of only family practitioners and pediatricians – and more than half are not satisfied with their incomes, according to the Endocrinologist 2015 Compensation Report, part of the overall Physician 2015 Compensation Report prepared by Medscape. The report found that endocrinologists tie with internists on an income of $196,000 per annum, ahead of family physicians at $195,000 and pediatricians, who receive $189,000. If they had to do it all over again, 63% of endocrinologists said they would still chose medicine as a career, and 45% would opt for the specialty of endocrinology once more.
להמשך קריאה

Paul Langerhans, a prodigious student

Paul Langerhans was born in Berlin on 25 July 1847, son of a Berlin physician, Paul Langerhans senior, also president of the Berlin City Council. Two of Paul brothers were physicians – Robert who was first assistant to Virchow and later occupied the Chair of Pathology and Richard, who practised in Berlin. Langerhans began his medical studies in the University of Jena, and then transferred to Friedrich Wilhelm University, Berlin, where he was a student of Rudolf Virchow. Langerhans’ first major histological discovery was in 1867, while still a medical student. Working in Virchow’s laboratory at the Berlin Pathological Institute, he investigated the innervation of the skin and demonstrated the non-pigmentary dendritic cells or stellate corpuscles which now bear his name. Langerhans had no idea of the function of these cells which are now known to be derived from the bone marrow and be the origin of Langerhans Histocytiosis. Langerhans’ most famous histological discovery, the pancreatic islets, was also made while still a medical student working on his MD thesis which he defended publicly on 18 February 1869. In this medical classic, he described the microscopical appearance in the rabbit’s pancreas of the acinar glandular cells which secrete the pancreatic digestive enzymes but scattered among them, in the inter-acinar spaces, were “small cells of almost perfect homogeneous content and of a polygonal form, with round nuclei without nucleoli, mostly lying together in pairs or small groups”. It was not until 1893 that E Laguesse of Lille first postulated these cells might produce internal secretion and named them ‘les ilots de Langerhans‘.  In 1870 Langerhans travelled to Egypt, Palestine and Syria making several anthropological observations. During the Franco-Prussian war he served with the German army as medical officer. In 1871, Langerhans was appointed prosector in pathology at the University of Freiburg in Breisgau and was soon elevated to the chair of pathology. In 1874, aged 27, he was diagnosed as having pulmonary tuberculosis and forced to abandon his academic career. In 1875 he settled in Madeira for its beneficial climate and after his health improved he set himself back in medical practice in Funchal, Madeira. In 1885 he married Margarethe Ebert. A daughter was born to them. Three years later he became seriously ill with a renal infection and died in Funchal on 20 July 1888 at the tragically early age of 41. He was buried in the British cemetery in Funchal

Source: Journal of the Royal Society of Medicine Volume 81 July 1988

להתראות בגיליון הבא !

עורך: פרופ’ קרלוס בן בסט
carlosb@netvision.net.il